Clinical Trial Update: Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating BMS-754807 in combination with Herceptin in advanced or metastatic HER2-positive breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BMS-754807 (BMS-754807)
• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED